Brief: UK's MHRA Approves Retifanlimab For Treatment Of Advanced Merkel Cell Skin Cancer
06/07/2026 12:10
BRIEF-UK's MHRA Approves Retifanlimab For Treatment Of Advanced Merkel Cell Skin Cancer July 6 (Reuters) - UK'S MHRA:
UK'S MHRA: APPROVES RETIFANLIMAB (ZYNYZ) FOR THE TREATMENT OF ADVANCED MERKEL CELL SKIN CANCER
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler